Patents Represented by Attorney John C. Todaro
-
Patent number: 7632832Abstract: Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: January 13, 2006Date of Patent: December 15, 2009Assignee: Merck & Co., Inc.Inventors: Christopher S. Burgey, Theresa M. Williams, Zhengwu J. Deng, Craig A. Stump
-
Patent number: 7390798Abstract: The present invention is directed to compounds of Formula I: I (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.Type: GrantFiled: February 9, 2005Date of Patent: June 24, 2008Assignee: Merck & Co., Inc.Inventors: Theresa M. Williams, Christopher S. Burgey, Thomas J. Tucker, Craig A. Stump, Ian M. Bell
-
Patent number: 7342009Abstract: Compounds of formula I: inhibit the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.Type: GrantFiled: May 14, 2004Date of Patent: March 11, 2008Assignee: Merck & Co., Inc.Inventors: Kevin Dinnell, Timothy Harrison, Alan John Nadin, Andrew Pate Owens, Duncan Edward Shaw, Brian John Williams
-
Patent number: 7285393Abstract: There is provided an assay for identifying compounds which interact with the ?-secretase complex, in particular compounds that lower the production of A?42.Type: GrantFiled: December 18, 2003Date of Patent: October 23, 2007Assignee: Merck Sharp & Dohme LimitedInventor: D. Beher
-
Patent number: 7271191Abstract: The compounds of formula I: inhibit gamma secretase and hence are of utility in the treatment or prevention of Alzheimer's Disease.Type: GrantFiled: April 1, 2004Date of Patent: September 18, 2007Assignee: Merck Sharp & Dohme Ltd.Inventors: Michela Bettati, Mark Stuart Chambers, Peter Alan Hunt, Philip Jones, Angus Murray MacLeod, Helen Jane Szekeres, Martin Richard Teall
-
Patent number: 7205434Abstract: There is disclosed a novel class of sulphonamido-substituted bridged bicycloalkyl derivatives comprising a substitute on the bridgehead position. The compounds modulate the production of the ?-amyloid precursor protein, and hence are useful in the treatment of Alzheimer's Disease.Type: GrantFiled: July 31, 2002Date of Patent: April 17, 2007Assignee: Merck Sharp & Dohme Ltd.Inventors: Joanne Clare Hannam, Timothy Harrison, Andrew Madin, Timothy Jason Sparey
-
Patent number: 7205336Abstract: The present invention provides compounds that are inhibitors of the proteolytic activity of the enzyme ?-secretase, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, processes for making the compounds, and methods of using the compounds to treat Alzheimers disease.Type: GrantFiled: May 14, 2003Date of Patent: April 17, 2007Assignee: Merck & Co., Inc.Inventors: Ming-Tain Lai, Ming-Chih Crouthamel, Stephen F. Brady
-
Patent number: 7183303Abstract: Compounds of formula I: inhibit gamma-secretase and hence find use in treatment of Alzheimer's disease.Type: GrantFiled: November 5, 2004Date of Patent: February 27, 2007Assignee: Merck Sharp & Dohme LimitedInventors: Jose Luis Castro Pineiro, Ian James Collins, Timothy Harrison
-
Patent number: 7161006Abstract: The invention provides compounds of formula I: which are inhibitors of ?-secretase and hence useful in the treatment or prevention of Alzheimer's disease.Type: GrantFiled: September 25, 2003Date of Patent: January 9, 2007Assignee: Merck Sharp & Dohme LimitedInventors: James Michael Crawforth, Jason Matthew Elliott, Andrew Pate Owens, Francine Sternfeld
-
Patent number: 7157478Abstract: Compounds of formula I: wherein X represents a 5-(R-substituted)-1,2,4-oxadiazole-3-yl moiety are inhibitors of gamma-secretase, and hence useful for treating Alzheimer's diseaseType: GrantFiled: April 24, 2003Date of Patent: January 2, 2007Assignee: Merck Sharp & Dohme Ltd.Inventors: Ian James Collins, Laura Catherine Cooper
-
Patent number: 7148236Abstract: The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.Type: GrantFiled: July 29, 2002Date of Patent: December 12, 2006Assignee: Merck & Co., Inc.Inventors: Peter Charles Astles, Stephen Richard Baker, Rowena Villanueva Cube, Jose Antonio Martinez-Perez, Ana Isabel Mateo Herranz, Jean Michel Vernier, Colin Peter Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Jan Sanderson, Colin William Smith
-
Patent number: 7144910Abstract: Compounds of formula I: inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.Type: GrantFiled: October 29, 2003Date of Patent: December 5, 2006Assignee: Merck Sharp & Dohme LimitedInventors: Andrew Madin, Mark Peter Ridgill
-
Patent number: 7144887Abstract: The present invention provides a compound of formula (I) in which R1 is generally hydrogen or CF3, R2 is generally hydrogen, W is a cyclic amine, a heterocycle or a group L-Y—X where L-Y is a linking portion and X is generally an aromatic or non-aromatic heterocycle, alkyl or alkylcarbonyl and Z is generally a heterocycle such as 5-methylisoxazol-3-yl, and pharmaceutically acceptable salts thereof for enhancing cognition in conditions such as Alzheimer's Disease, pharmaceutical compositions comprising them, their use for manufacturing medicaments and methods of treatment using themType: GrantFiled: December 11, 2000Date of Patent: December 5, 2006Assignee: Merck Sharp & Dohme Ltd.Inventors: Helen Jane Bryant, Mark Stuart Chambers, Philip Jones, Angus Murray MacLeod, Robert James Maxey
-
Patent number: 7138400Abstract: Novel sulfamides of formula (I) are disclosed. The compounds exert an inhibitory action on the processing of APP by gamma-secretase, and are therefore useful in the treatment or prevention of Alzheimer's disease.Type: GrantFiled: October 29, 2001Date of Patent: November 21, 2006Assignee: Merck Sharp & Dohme LimitedInventors: Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Timothy Jason Sparey, Brian John Williams
-
Patent number: 7109217Abstract: Disclosed are compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved.Type: GrantFiled: November 6, 2003Date of Patent: September 19, 2006Assignee: Merck & Co., Inc.Inventors: Craig A. Coburn, Shawn J. Stachel, Joseph P. Vacca
-
Patent number: 7105509Abstract: A novel class of 1,4- and 1,5-benzodiazepines of formula (I) is disclosed.Type: GrantFiled: May 21, 2001Date of Patent: September 12, 2006Assignee: Merck Sharp & Dohme LimitedInventors: Jose Luis Castro Pineiro, Ian Churcher, Alexander Richard Guiblin, Timothy Harrison, Sonia Kerrard, Andrew Madin, Alan John Nadin, Andrew Pate Owens, Timothy Jason Sparey, Martin Richard Teall, Susannah Williams
-
Patent number: 7101895Abstract: Compounds of formula I: wherein Ar1 and Ar2 are optionally substituted aryl or heteroaryl, L is a bond, ?CH— or —(CHRa)n—, and X is SCN, SR1, S(O)R1, (CRaRb)mSO2R1, SO2N(R2)2, SO2NHCOR1, SO2NHN(R2)2, OSO2N(R2)2, OS(O)N(R2)2, OSO2NHCOR1, COR4, NHCOR1, NHCO2R1, NHCON(R2)2, NHSO2R1 or NHSO2N(R2)2, inhibit the processing of APP by gamma secretase, and hence are useful in treatment of Alzheimer's disease.Type: GrantFiled: October 6, 2003Date of Patent: September 5, 2006Assignee: Merck Sharp & Dohme LimitedInventors: Ian Churcher, Timothy Harrison, Sonia Kerrad, Paul Joseph Oakley, Duncan Edward Shaw, Martin Richard Teall, Susannah Williams
-
Patent number: 7060710Abstract: The present invention provides compounds of formula I: in which: one of X and Y is a nitrogen atom substituted by a group R6? and the other is a carbon atom substituted by an isoxazole group substituted on its carbon atoms by groups R3 and R4; one of R6 and R6? is hydrogen; either all of W1, W2, W3 and W4 are carbon or one of W1, W2, W3 and W4 is nitrogen and the rest are carbon; and R1 and R2 are, independently, a small group, heteroaromatic ring or a 4–7 membered cyclic amine ring; processes for making them; pharmaceutical composition containing them; their use in therapy, particularly for enhancing cognition in conditions such as Alzheimer's Disease; and methods of treatment using them.Type: GrantFiled: November 22, 2002Date of Patent: June 13, 2006Assignee: Merck Sharp & Dohme Ltd.Inventors: Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Francine Sternfeld
-
Patent number: 7049296Abstract: Urea derivatives of formula I are disclosed: The compounds are inhibitors of ?-secretase, and hence useful in the treatment or prevention of Alzheimer's DiseaseType: GrantFiled: February 28, 2001Date of Patent: May 23, 2006Assignee: Merck Sharp & Dohme Ltd.Inventors: Jose Luis Castro Pineiro, Adrian Leonard Smith, Graeme Irvine Stevenson
-
Patent number: 7041688Abstract: Compounds of formula (I) are disclosed.Type: GrantFiled: April 24, 2003Date of Patent: May 9, 2006Assignee: Merck Sharp & Dohme Lt.d.Inventors: Alister Campbell, Mark Peter Ridgill